Bionano Genomics Q2 revenue up 30% to $8.7M; flowcell sales more than double YoY

Bionano Genomics, Inc.

2023-Q2 EPS reported -$2.46 revenue$16,077,000

Q2 2023 revenue $8.7M, +30% YoY; GAAP gross margin 27% vs 22%.
Installed Saphyr systems 281 (+43% YoY); flowcells sold 7,062 (+108% YoY).
GAAP operating expense $41.5M vs $33.6M; non-GAAP opEx $34.6M.
Cash & securities $77.1M at June 30, down from $95.8M at March 31.
Announced Stratys high-throughput OGM system and VIA software for hematologic malignancies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bionano Genomics, Inc. reported second quarter ended June 30, 2023 results: revenue $8.7 million.

Period: second quarter ended June 30, 2023
Revenue: $8.7 million
Result: reported results

Exact text from the filing

filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress • Q2 2023 revenue was $8.7 million, which represents a 30% increase over Q2 2022 • Installed base of Saphyr ® systems totaled 281 as of June 30, 2023, which represents a 43% increase over Q2 2022 • Sold 7,062

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001411690-23-000067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.